12 ‘Kovid-19 vaccine’ studies are conducted in Turkey

AA | Wednesday, May 05, 2021 – 17:01 | Last Updated: 05 05 2021 – 17:01

Selcuk University Vaccine Development and Application Center Manager Prof. Dr. Erganiş said, “Research and development processes continue in these vaccine studies. Some of them are carrying out phase-1 and phase-2 studies. Some of them continue their clinical studies.” said.

Selcuk University (SU) Vaccine Development and Application Center Director Prof. Dr. Osman Erganiş reported that 12 Kovid-19 vaccine studies are continuing in Turkey.

Prof. Dr. Erganiş participated in the “6th Biotechnology Days” organized online by Tekirdağ Namık Kemal University (NKU) Biotechnology Society and Faculty of Agriculture Department of Agricultural Biotechnology, and made a presentation on “Kovid-19 Vaccine Studies in Turkey”.

In his presentation, Erganiş said that the Kovid-19 vaccine development studies in Turkey were supported by the Scientific and Technological Research Council of Turkey (TÜBİTAK) and the Turkish Health Institutes (TÜSEB) affiliated to the Ministry of Health.

Reminding that after the Kovid-19 epidemic started to appear in the world, studies on vaccines, diagnostic kits and measures to be taken were started in Turkey before the case was seen, Erganiş stated that important research and development studies were carried out in this process.

Emphasizing that the Kovid-19 vaccine development studies in Turkey continue uninterruptedly and researchers are working hard, Erganiş said, “There are 12 vaccine studies in Turkey supported by TÜBİTAK and TÜSEB in the World Health Organization’s Kovid-19 vaccine studies list. Research and development processes in these vaccine studies continue. Some of them are in phase-1 and phase-2 studies, and some are in clinical trials. ” said.

Erganiş stated that the vaccine development, research and production processes consisted of many presses.

Emphasizing the importance of the vaccine in combating the epidemic, Erganiş said, “World companies and governments have turned to the product rapidly and shortened the process during the pandemic process. High and long-term protection is not expected for SARS-COV-2, which is an RNA virus. protection is expected. We should be producing our own vaccine as soon as possible. ” he spoke.